STOCK TITAN

Fortrea Holdings (FTRE) Stock Price, News & Analysis

FTRE NASDAQ
Published by Stock Titan Data refreshed

What Changed

Price Move History

Daily moves over 5%
48 252 sessions, November 17, 2025 to November 17, 2026
Largest daily move
+18.6% close of May 5, 2026
1-year change
+100.1% closing prices, November 17, 2025 to November 17, 2026
1-month change
-12.9% closing prices, October 16, 2026 to November 17, 2026

Company Description

Fortrea Holdings Inc. (NASDAQ: FTRE) is a global contract research organization (CRO) and provider of clinical development solutions to the life sciences industry. The company is classified in the Professional, Scientific, and Technical Services sector and the Testing Laboratories industry. Fortrea works with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to support the development of therapies from early clinical stages through late-stage studies.

According to company disclosures, Fortrea delivers phase I–IV clinical trial management, clinical pharmacology and consulting services. Its offerings are aimed at helping customers run clinical trials and advance potential treatments for patients. Fortrea states that its solutions build on three decades of experience across more than 20 therapeutic areas, emphasizing scientific rigor, insights from clinical development, and access to an investigator site network.

Fortrea describes itself as a global provider, with a team working in about 100 countries. This geographic reach is intended to support customers that run multinational clinical studies and need consistent processes and oversight across regions. The company highlights its ability to partner with both emerging and large organizations across the life sciences value chain.

In addition to the operational aspects of clinical development, Fortrea’s public communications reference its role in the broader financial and corporate landscape. The company’s common stock is listed on The NASDAQ Stock Market LLC under the symbol FTRE, and it has also registered rights to purchase Series A preferred stock. Fortrea has reported quarterly financial results, issued guidance, and engaged in capital structure actions such as a tender offer for senior secured notes, as reflected in its press releases and Form 8-K filings.

Fortrea has also used equity-based inducement awards under a dedicated inducement award plan for new hires, as disclosed in its SEC filings. The company’s board and leadership changes, including director appointments and executive roles such as general counsel, are documented through current reports on Form 8-K, indicating ongoing corporate governance activity.

Fortrea’s origins as a clinical development business that became an independent, publicly traded company are noted in third-party descriptions. The company is described as having been formed after a spin-off of a clinical development business previously owned by another organization. This background provides context for its focus on late-stage clinical development and its positioning as a CRO serving a wide range of life sciences customers.

Business focus and services

Fortrea’s core business centers on providing clinical development solutions. Based on company descriptions, these solutions include:

  • Phase I–IV clinical trial management for biopharmaceutical, biotechnology, medical device and diagnostic companies.
  • Clinical pharmacology services, which support the study of how potential therapies behave in the body.
  • Consulting services related to clinical development.

The company positions these services as contributing to healthcare innovation by helping customers accelerate the development of life-changing therapies for patients. Its experience across numerous therapeutic areas and its investigator site network are presented as key elements of its operating model.

Industry context

Within the Testing Laboratories industry and the broader Professional, Scientific, and Technical Services sector, Fortrea operates as a contract research organization focused on clinical development. CROs typically support life sciences companies by managing and executing clinical studies and related activities. Fortrea’s own statements emphasize its role in partnering with customers across different sizes and segments of the life sciences industry.

Geographic footprint

Fortrea reports that its team works in about 100 countries. This global footprint is intended to support clinical development programs that require access to diverse patient populations and investigator sites. The company’s headquarters city is identified in multiple news releases as Durham, North Carolina.

Regulatory and public company status

Fortrea files reports with the U.S. Securities and Exchange Commission (SEC) as a public company. Recent Form 8-K filings show that:

  • Its common stock, with a par value of $0.001 per share, is registered and trades under the symbol FTRE on The NASDAQ Stock Market LLC.
  • Rights to purchase Series A preferred stock are also registered on the same exchange.
  • The company periodically reports results of operations and financial condition through press releases furnished as exhibits to Form 8-K.
  • Corporate actions such as a debt tender offer for senior secured notes and amendments to an inducement award plan are disclosed via Form 8-K.

These filings provide insight into Fortrea’s financial reporting, capital structure management, and governance practices.

Company history

Third-party descriptions indicate that Fortrea was formed as an independent, publicly traded company after a spin-off of a clinical development business from another organization. That clinical development business had previously been acquired through a transaction involving Covance. This history underpins Fortrea’s emphasis on three decades of experience in clinical development and its focus on late-stage contract research activities.

Use cases for investors and observers

For investors and others researching FTRE stock, Fortrea represents exposure to a contract research organization that operates in the life sciences clinical development space. Public information highlights:

  • Its role as a global provider of clinical development solutions.
  • Its customer base across biopharmaceutical, biotechnology, medical device and diagnostic companies.
  • Its presence in numerous therapeutic areas.
  • Its public company status on NASDAQ and ongoing SEC reporting.

Fortrea’s press releases also discuss topics such as quarterly financial performance, guidance, cost-saving initiatives, debt tender offers, leadership appointments, and collaborations with other organizations in areas like cell and gene therapy development.

Stock Performance

$20.19
+3.06%
+0.60
Last updated: at
+100.1%
Performance 1 year

Fortrea Holdings (FTRE) closed at $19.59 on November 17, 2026. Over the past 12 months, the price has gained 100.1%.

See what a $1,000 investment in FTRE would be worth today

Average down calculator for FTRE

FTRE Metrics & Rankings

Price returns through November 17, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
3,395
Shares Sold
2
Transactions
Most Recent Transaction
Russell Carrie Elizabeth (Interim CAO) sold 246 shares @ $16.85 on September 9, 2026

Insider selling at Fortrea Holdings over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Fortrea Holdings generated $2.7B in revenue in FY2025, retaining a 18.5% gross margin, operating income reached -$872.6M (-32.0% operating margin), and net income was -$986.2M, reflecting a -36.2% net profit margin. Diluted earnings per share stood at -$10.81. The company generated $113.5M in operating cash flow. The current ratio was 0.98, measuring current assets divided by current liabilities.

$2.7B
Revenue (FY2025)
-$986.2M
Net Income (FY2025)
$113.5M
Operating Cash Flow

Upcoming Events

NOV
17
November 17, 2026 - November 17, 2026 Marketing

Jefferies Fireside Chat

Jefferies Global Healthcare Conference fireside chat in London; 08:30–08:55 EST (2026-11-17), webcast and replay on Fortrea IR site.
DEC
10
December 10, 2026 Corporate

RSU first vesting

One-third of 245,000 RSUs vesting; subject to continued employment; governed by inducement plan.
MAR
10
March 10, 2027 Corporate

RSU vesting 1st installment

Approx 43,333 of 130,000 RSUs vest; subject to continuous employment and 2025 Inducement Plan
JUN
10
June 10, 2027 Corporate

RSU vesting installment 1

First of three annual installments: 240,500 RSUs vest on this date for 10 hires under the 2025 Inducement Award Plan; Nasdaq rule cited.
SEP
10
September 10, 2027 Corporate

First RSU vesting

First of three equal annual vesting installments of 144,434 RSUs granted to CFO Jason Knoblauch under Fortrea plan.
DEC
10
December 10, 2027 Corporate

RSU second vesting

One-third of 245,000 RSUs vesting; subject to continued employment; governed by inducement plan.
MAR
10
March 10, 2028 Corporate

RSU vesting 2nd installment

Approx 43,333 of 130,000 RSUs vest; subject to continuous employment and 2025 Inducement Plan
JUN
10
June 10, 2028 Corporate

RSU vesting installment 2

Second annual installment: remaining RSUs vest for 10 hires under the 2025 Inducement Award Plan; potential dilution consideration.
SEP
10
September 10, 2028 Corporate

Second RSU vesting

Second annual installment vesting of 144,434 RSUs awarded to CFO Jason Knoblauch under Fortrea’s 2025 Inducement Award Plan.
DEC
10
December 10, 2028 Corporate

RSU final vesting

One-third of 245,000 RSUs vesting; subject to continued employment; governed by inducement plan.
MAR
10
March 10, 2029 Corporate

RSU vesting final installment

Approx 43,334 of 130,000 RSUs vest; subject to continuous employment and 2025 Inducement Plan
JUN
10
June 10, 2029 Corporate

RSU vesting installment 3

Final annual installment: remaining RSUs vest for 10 hires under the 2025 Inducement Award Plan; subject to Nasdaq Listing Rule 5635(c)(4).
SEP
10
September 10, 2029 Corporate

Final RSU vesting

Final annual installment vesting of 144,434 RSUs to CFO Jason Knoblauch; subject to continuous employment and plan terms.
SEP
10
September 10, 2029 Corporate

PSU performance vesting

Potential vesting of 106,755 performance share units granted to CFO Jason Knoblauch at end of the three‑year performance period.

Fortrea Holdings has 14 upcoming scheduled events. Investors can track these dates to stay informed about potential catalysts that may affect the FTRE stock price.

Short Interest History

Last 12 Months

Short interest in Fortrea Holdings (FTRE) currently stands at 8.6 million shares, up 11.7% from the previous reporting period, representing 9.0% of the float. Since November 2025, short interest has decreased by 13.5%.

Days to Cover History

Last 12 Months

Days to cover for Fortrea Holdings (FTRE) currently stands at 3.7 days, down 8.1% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has decreased by 52.2%. Across the settlements charted above, it has ranged from 3.7 to 11.9 days.

FTRE Company Profile & Sector Positioning

Fortrea Holdings (FTRE) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing FTRE often look at related companies in the same sector, including Maravai LifeSciences Holdings, Inc. (MRVI), Recursion Pharmaceuticals, Inc. (RXRX), Agios Pharmaceuticals, Inc. (AGIO), Zymeworks Inc. (ZYME), and Trevi Therapeutics, Inc. (TRVI). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate FTRE's relative position within its industry.

Frequently Asked Questions

The current stock price of Fortrea Holdings (FTRE) is $20.19 as of November 18, 2026.

The market cap of Fortrea Holdings (FTRE) is approximately $1.9B. Learn more about what market capitalization means .

The FY2025 revenue of Fortrea Holdings (FTRE) is $2.7B, from its most recent completed fiscal year.

The FY2025 net income of Fortrea Holdings (FTRE) is -$986.2M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Fortrea Holdings (FTRE) is -$10.81 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Fortrea Holdings (FTRE) is $113.5M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Fortrea Holdings (FTRE) is -36.2% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Fortrea Holdings (FTRE) is -32.0% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Fortrea Holdings (FTRE) is 18.5% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Fortrea Holdings (FTRE), current assets divided by current liabilities, was 0.98 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Fortrea Holdings (FTRE) is $503.8M for FY2025, its most recent completed fiscal year.

The operating income of Fortrea Holdings (FTRE) is -$872.6M for FY2025, its most recent completed fiscal year. Learn about operating income.

Fortrea Holdings Inc. is a global contract research organization and provider of clinical development solutions to the life sciences industry. It focuses on services such as phase I–IV clinical trial management, clinical pharmacology and consulting for biopharmaceutical, biotechnology, medical device and diagnostic companies.

Fortrea is classified in the Testing Laboratories industry within the Professional, Scientific, and Technical Services sector.

Company descriptions state that Fortrea provides phase I–IV clinical trial management, clinical pharmacology services and consulting services. These offerings are intended to support customers throughout the clinical development lifecycle.

Fortrea reports that it partners with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies that are developing therapies and medical technologies.

Fortrea states that its talented and diverse team works in about 100 countries. This global footprint supports customers running clinical trials across multiple regions.

Fortrea’s common stock, with a par value of $0.001 per share, is listed on The NASDAQ Stock Market LLC under the ticker symbol FTRE. Rights to purchase Series A preferred stock are also registered on NASDAQ.

Fortrea indicates that its solutions leverage three decades of experience across more than 20 therapeutic areas, supported by scientific rigor, insights and an investigator site network.

Fortrea reports financial results through press releases that are furnished as exhibits to Form 8-K filings with the SEC. These releases discuss items such as revenue, net income or loss, adjusted measures and guidance for future periods.

Yes. Fortrea has disclosed a tender offer to purchase a portion of its outstanding 7.500% senior secured notes due 2030, as described in an Offer to Purchase referenced in its press releases and Form 8-K filings.

According to an 8-K filing, Fortrea’s board amended and restated the Fortrea Holdings Inc. 2025 Inducement Award Plan to increase the number of shares reserved for issuance. The plan may be used exclusively for inducement awards to individuals who were not previously employees or directors, as permitted under Nasdaq Listing Rule 5635(c)(4).